CIP2A confirms its prognostic value in triple-negative breast cancer

Oncogene. 2017 Jun 8;36(23):3357-3358. doi: 10.1038/onc.2016.474. Epub 2017 Jan 9.

Authors

I Cristóbal¹, S Zazo², B Torrejón¹, M Pedregal¹, J Madoz-Gúrpide², A Lluch³, P Eroles³, A Rovira⁴, J Albanell⁴, J García-Foncillas¹, F Rojo²

Affiliations

¹ Department of Medical Oncology, Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundacion Jimenez Diaz', Madrid, Spain.
² Department of Pathology, IIS 'Fundación Jiménez Diaz', Madrid, Spain.
³ Department of Breast Cancer Research, Institute of Health Research INCLIVA, Valencia, Spain.
⁴ Department of Medical Oncology, Hospital del Mar, Barcelona, Spain.

PMID: 28068327
DOI: 10.1038/onc.2016.474

No abstract available

Publication types

Letter
Comment

MeSH terms

Autoantigens
Biomarkers, Tumor
Breast Neoplasms
Cell Line, Tumor*
Humans
Prognosis
Triple Negative Breast Neoplasms*

Substances

Autoantigens
Biomarkers, Tumor